Heptanamide, 7-[3-[[6-amino-4-(2-furanyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]phenoxy]-N-hydroxy- manufacturers
- A2AAR/HDAC-IN-2
-
- $1980.00
-
2026-04-20
- CAS:2767560-94-9
- Purity:
- Supply Ability: 10g
|
| | Heptanamide, 7-[3-[[6-amino-4-(2-furanyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]phenoxy]-N-hydroxy- Basic information |
| | Heptanamide, 7-[3-[[6-amino-4-(2-furanyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]phenoxy]-N-hydroxy- Chemical Properties |
| density | 1.39±0.1 g/cm3(Predicted) | | pka | 9.48±0.20(Predicted) |
| | Heptanamide, 7-[3-[[6-amino-4-(2-furanyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]phenoxy]-N-hydroxy- Usage And Synthesis |
| Uses | A2AAR/HDAC-IN-2 is a potent A2AAR/HDAC dual inhibitor, with good binding affinity for A2AAR (Ki=10.3 nM) and good inhibitory activity against HDAC1 (IC50=18.5 nM). A2AAR/HDAC-IN-2 can be used in study of antitumor[1]. | | IC 50 | HDAC1: 18.5 nM (IC50); HDAC2: 16.0 nM (IC50); HDAC3: 13.6 nM (IC50); HDAC6: 2.1 nM (IC50); HDAC8: 1408.9 nM (IC50); A1AR: 105.6 nM (Ki); A2AAR: 10.3 nM (Ki); A2BAR: 513.0 nM (Ki); A3AR: ＞10 μM (IC50) | | References | [1] Zhang J, et al. Dual-acting antitumor agents targeting the A2A adenosine receptor and histone deacetylases: Design and synthesis of 4-(furan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amine derivatives. Eur J Med Chem. 2022 Jun 5;236:114326. DOI:10.1016/j.ejmech.2022.114326 |
| | Heptanamide, 7-[3-[[6-amino-4-(2-furanyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]methyl]phenoxy]-N-hydroxy- Preparation Products And Raw materials |
|